Kintara Therapeutics, Inc.
At Close: 4:00 PM
Kintara Therapeutics, Inc.
KTRA Stock Price Today
Kintara Therapeutics, Inc. (KTRA) stock declined over -4.93% intraday to trade at $6.56 a share on NASDAQ. The stock opened with a loss of -2.90% at $6.7 and touched an intraday high of $7.65, falling -4.93% against the last close of $6.9. The Kintara Therapeutics, Inc. in stock market went to a low of $6.271 during the session.
Number of Shares
Cash Flow per Share
Free Float in %
Sales or Revenue-
5Y Sales Change-
Fiscal Year EndsJun. 2022
Kintara Therapeutics, Inc., a clinical stage drug development company, focuses on developing and commercializing anti-cancer therapies to treat cancer patients. It is developing two late-stage, Phase III-ready therapeutics, including VAL-083, a DNA-targeting agent for the treatment of drug-resistant solid tumors, such as glioblastoma multiforme, as well as other solid tumors, including ovarian cancer, non-small cell lung cancer, and diffuse intrinsic pontine glioma; and REM-001, a photodynamic therapy for the treatment of cutaneous metastatic breast cancer. The company has a strategic collaboration with Guangxi Wuzhou Pharmaceutical (Group) Co. Ltd. to manufacture and sell VAL-083 in China. The company was formerly known as DelMar Pharmaceuticals, Inc. and changed its name to Kintara Therapeutics, Inc. in August 2020. Kintara Therapeutics, Inc. was incorporated in 2009 and is headquartered in San Diego, California.
Frequently Asked Questions
What is the current Kintara Therapeutics, Inc. (KTRA) stock price?
Kintara Therapeutics, Inc. (NASDAQ: KTRA) stock price is $6.56 in the last trading session. During the trading session, KTRA stock reached the peak price of $7.65 while $6.271 was the lowest point it dropped to. The percentage change in KTRA stock occurred in the recent session was -4.93% while the dollar amount for the price change in KTRA stock was -$0.34.
KTRA's industry and sector of operation?
The NASDAQ listed KTRA is part of Biotechnology industry that operates in the broader Health Care sector. Kintara Therapeutics, Inc. , a clinical stage drug development company, focuses on developing and commercializing anti-cancer therapies to treat cancer patients.
Who are the executives of KTRA?
Mr. Robert E. Hoffman B.B.A., CPA, CPA
Pres, CEO & Chairman
Dr. Dennis M. Brown B.Sc., M.A., Ph.D.
Co-Founder & Chief Scientific Officer
Mr. Scott Praill B.Sc., C.P.A., CA, CPA, BSc
CFO & Sec.
Mr. Jeffrey A. Bacha B.Sc., M.B.A.
How KTRA did perform over past 52-week?
KTRA's closing price is 0.87% higher than its 52-week low of $3.502 where as its distance from 52-week high of $42 is -0.84%.
How many employees does KTRA have?
Number of KTRA employees currently stands at 3. KTRA operates from 12707 High Bluff Drive, Suite 200, San Diego, CA 92130, United States.
Link for KTRA official website?
Official Website of KTRA is: https://www.kintara.com
How do I contact KTRA?
How many shares of KTRA are traded daily?
KTRA stock volume for the day was 58,191 shares. The average number of KTRA shares traded daily for last 3 months was 390.27 Thousands.
What is the market cap of KTRA currently?
The market value of KTRA currently stands at $11.22 Million with its latest stock price at $6.56 and 1.62 Million of its shares outstanding.